American Journal of Respiratory and Critical Care Medicine · 2024 · 12 citations · 41 references
Life SciencesCell BiologyMolecular BiologyCell TherapyStem Cell BiologyTranscriptomicsBronchopulmonary DysplasiaLung DevelopmentMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapySingle-cell AnalysisSingle-cell Rna Sequencing AnalysisLung ProtectionMesenchymal Stromal Cell CharacterizationMesenchymal Stromal Cell Clinical TrialsPrematurity-related Respiratory MorbidityTranscriptome AnalysisTranscriptomic ProfilesUmbilical Cord-derived Mesenchymal Stem CellsUmbilical Cord-derived Mesenchymal Stromal Cells
Abstract Rationale The chronic lung disease bronchopulmonary dysplasia (BPD) is the most severe complication of extreme prematurity. BPD results in impaired lung alveolar and vascular development and long-term respiratory morbidity, for which only supportive therapies exist. Umbilical cord–derived mesenchymal stromal cells (UC-MSCs) improve lung structure and function in experimental BPD. Results of clinical trials with MSCs for many disorders do not yet match the promising preclinical studies. A lack of specific criteria to define functionally distinct MSCs persists. Objectives To determine and correlate single-cell UC-MSC transcriptomic profiles with therapeutic potential. Methods UC-MSCs from five term donors and human neonatal dermal fibroblasts (HNDFs; control cells of mesenchymal origin) transcriptomes were investigated using single-cell RNA sequencing (scRNA-seq) analysis. The lung-protective effect of UC-MSCs with a distinct transcriptome and control HNDFs was tested in vivo in hyperoxia-induced neonatal lung injury in rats. Measurements and Main Results UC-MSCs showed limited transcriptomic heterogeneity but were different from HNDFs. Gene Ontology enrichment analysis revealed distinct (progenitor-like and fibroblast-like) UC-MSC subpopulations. Only treatment with progenitor-like UC-MSCs improved lung function and structure and attenuated pulmonary hypertension in hyperoxia-exposed rat pups. Moreover, scRNA-seq identified major histocompatibility complex class I as a molecular marker of nontherapeutic cells and associated with decreased lung retention. Conclusions UC-MSCs with a progenitor-like transcriptome, but not with a fibroblast-like transcriptome, provide lung protection in experimental BPD. High expression of major histocompatibility complex class I is associated with reduced therapeutic benefit. scRNA-seq may be useful to identify subsets of MSCs with superior repair capacity for clinical application.
41
Comprehensive Integration of Single-Cell Data
Tim Stuart, Andrew Butler, Paul Hoffman et al. · Cell · 2019 · 16.9K citations · Full text
Alan H. Jobe, Eduardo Bancalari · American Journal of Respiratory and Critical Care Medicine · 2001 · 4.8K citations
Medicine, Child Health, Pediatrics +15